Smithkline Beecham Corporation

Glaxo Wellcome Inc.

Other

University College Cardiff Consultants Limited

Inhibitex, Inc.

Purthread Technologies, Inc.

Glaxosmithkline LLC

Stanley Dawes Chamberlain

Brian Alvin Johns

Kristjan S Gudmundsson

George Walter Koszalka

Mui Cheung

Jeffrey H Tidwell

Susan Mary Daluge

Philip Anthony Harris

David Kendall Jung

Michael Robert Peel

Leroy B Townsend

John Charles Drach

Stephen Woodrow Foss

Michael John Alberti

John Vernachio

George Andrew Freeman

Lloyd Frick

Holly Kathleen Emerson

Karolina Madela

Jennifer Badiang Stanford

Nanine Agneta Vandraanen

Christopher McGuigan

Neil W Johnson

David Lee Musso

Marc W Andersen

David Norman Deaton

Aniko Redman

Jeff T Hutchins

Joseph Wendell Wilson

Kevin Kuntz

Huangshu Lei

Jennifer Gabriel Badiang

Kirk Stevens

John Brad Shotwell

Douglas McCord Sammond

Gregory Peckham

Masaichi Hasegawa

Yasushi Miyazaki

Kristen Elizabeth Nailor

Marcus Semones

F Leslie Boyd

Felix Deanda, Jr

Frank Leslie Boyd, Jr

Naohiko Nishigaki

Chris McGuigan

Connie Jo Sexton

Claire Bourdin

Roseanne Gerding

Joseph H Chan

Mohamed Aljarah

Samarjit Patnaik

Arnaud Gilles

Bin Yang

High-melting antimicrobial polymer fibers and antimicrobial fabrics comprising such fibers are prepared by preparing a masterbatch of polymer pellets (e.g., PET), silver and copper salts, and a compounding agent which provides free flowing polymer pellets which can be prepared in advance, with a long shelf life. Polymer masterbatches prepared by the methods of the invention can produce limited color or off-white antimicrobial fibers and fabrics using conventional melt spinning manufacturing methods. Fabrics incorporating fibers of the present invention are potent inhibitors of Athlete's foot fungi, gram negative and gram positive bacteria, and drug resistant pathogens.

Antimicrobial and antifungal polymer fibers, fabrics, and methods of manufacture thereof

This invention is directed to phosphoroamidate and phosphorodiamidate derivatives including the compounds of formula (I) having the structure wherein U, V, W, Z, R, X, X, and Y are defined herein. These compounds and pharmaceutical compositions containing these compounds are useful in the treatment of viral infections in mammals infected by a virus in the Flaviviridae family of viruses, in particular hepatitis C virus (HCV). The compounds of this invention may be prepared by various methods known in the art of organic chemistry in general and nucleoside and nucleotide analog synthesis in particular.

Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections

Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Pharmaceutical compositions, methods of preparing the compounds, and methods of using the compounds and compositions to treat viral infections are also provided.

Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections

Novel pyrrolopyrimidines as shown in formula (I): and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.

2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer

A crystal structure of the cfms kinase domain, co-crystal structure with a bound small molecule, as well as methods of using the same in the discovery of cfms inhibitors and in the treatment of diseases mediated by inappropriate cfms activity.

Crystal structure of liganded cFMS kinase domain

Benzimidazole derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Diamino-pyrimidines and their use as angiogenesis inhibitors

The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

Pyrazolopyridinyl pyrimidine therapeutic compounds

Therapeutic compounds

Pyrazolopyridines, process for their preparation and use as therapeutic compounds

The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents 

Pyralopyridines, process for their preparation and use as therapeutic compounds

The present invention provides compounds of formula (I):wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds

The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of restenosis.

Benzimidazole derivatives useful for treating or preventing viral infections such as those caused by herpes viruses or in the treatment of restenosis following surgical techniques. Methods of preparing these benzimidazole derivatives and pharmaceutical compositions containing them are described.

Benzimidazole derivatives

Growing community of inventors

Durham, NC, United States of America

Stanley Dawes Chamberlain